Cargando…
ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study
BACKGROUND: Expression of estrogen receptor alpha (ERα) is predictive for endocrine therapy response and an important prognostic factor in breast cancer. Overexpression of ERα can be caused by estrogen receptor 1 (ESR1) gene amplification and was originally reported to be a frequent event associated...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219866/ https://www.ncbi.nlm.nih.gov/pubmed/21541733 http://dx.doi.org/10.1007/s13402-011-0045-5 |
_version_ | 1782216907255971840 |
---|---|
author | Moelans, Cathy B. Monsuur, Hanneke N. de Pinth, Johannes H. Radersma, Remco D. de Weger, Roel A. van Diest, Paul J. |
author_facet | Moelans, Cathy B. Monsuur, Hanneke N. de Pinth, Johannes H. Radersma, Remco D. de Weger, Roel A. van Diest, Paul J. |
author_sort | Moelans, Cathy B. |
collection | PubMed |
description | BACKGROUND: Expression of estrogen receptor alpha (ERα) is predictive for endocrine therapy response and an important prognostic factor in breast cancer. Overexpression of ERα can be caused by estrogen receptor 1 (ESR1) gene amplification and was originally reported to be a frequent event associated with a significantly longer survival for ER-positive women treated with adjuvant tamoxifen monotherapy, which was however questioned by subsequent studies. METHODS: This study aimed to reanalyze the frequency of ESR1 amplification by multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridisation (FISH), and to assess clinicopathologic correlations. MLPA was performed in a group of 135 breast cancer patients, and gains/amplifications were subjected to FISH. RESULTS: True ESR1 amplification by MLPA was rare (2%) and only 6% more patients showed a modest gain of ESR1. All MLPA-detected ESR1 amplifications and nearly all ESR1 gains were also FISH amplified and gained, but not all FISH amplifications/gains were MLPA amplified/gained, leading to an overall concordance of only 60% between both techniques. All 3 MLPA and FISH ESR1 amplified cases had high ERα expression, but there was no obvious correlation between ESR1 gain and ER status by IHC. ESR1 gains/amplifications were not associated with HER2 gain/amplification, but seemed to be associated with older age. Surprisingly, ESR1 gain/amplification was not associated with low grade as reported previously, but correlated with high grade and high proliferation. Furthermore, ESR1 gain/amplification by MLPA was not associated with nodal status or tumor size (pT status). CONCLUSIONS: ESR1 amplification as detected by MLPA is rare in breast cancer, and seems to be associated with high ERα expression, high age, high grade and high proliferation. This study confirms previous studies that showed differences in the ESR1 amplification frequencies detected by different techniques. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13402-011-0045-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3219866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-32198662011-12-09 ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study Moelans, Cathy B. Monsuur, Hanneke N. de Pinth, Johannes H. Radersma, Remco D. de Weger, Roel A. van Diest, Paul J. Cell Oncol (Dordr) Original Paper BACKGROUND: Expression of estrogen receptor alpha (ERα) is predictive for endocrine therapy response and an important prognostic factor in breast cancer. Overexpression of ERα can be caused by estrogen receptor 1 (ESR1) gene amplification and was originally reported to be a frequent event associated with a significantly longer survival for ER-positive women treated with adjuvant tamoxifen monotherapy, which was however questioned by subsequent studies. METHODS: This study aimed to reanalyze the frequency of ESR1 amplification by multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridisation (FISH), and to assess clinicopathologic correlations. MLPA was performed in a group of 135 breast cancer patients, and gains/amplifications were subjected to FISH. RESULTS: True ESR1 amplification by MLPA was rare (2%) and only 6% more patients showed a modest gain of ESR1. All MLPA-detected ESR1 amplifications and nearly all ESR1 gains were also FISH amplified and gained, but not all FISH amplifications/gains were MLPA amplified/gained, leading to an overall concordance of only 60% between both techniques. All 3 MLPA and FISH ESR1 amplified cases had high ERα expression, but there was no obvious correlation between ESR1 gain and ER status by IHC. ESR1 gains/amplifications were not associated with HER2 gain/amplification, but seemed to be associated with older age. Surprisingly, ESR1 gain/amplification was not associated with low grade as reported previously, but correlated with high grade and high proliferation. Furthermore, ESR1 gain/amplification by MLPA was not associated with nodal status or tumor size (pT status). CONCLUSIONS: ESR1 amplification as detected by MLPA is rare in breast cancer, and seems to be associated with high ERα expression, high age, high grade and high proliferation. This study confirms previous studies that showed differences in the ESR1 amplification frequencies detected by different techniques. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13402-011-0045-5) contains supplementary material, which is available to authorized users. Springer Netherlands 2011-05-04 2011 /pmc/articles/PMC3219866/ /pubmed/21541733 http://dx.doi.org/10.1007/s13402-011-0045-5 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Original Paper Moelans, Cathy B. Monsuur, Hanneke N. de Pinth, Johannes H. Radersma, Remco D. de Weger, Roel A. van Diest, Paul J. ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study |
title | ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study |
title_full | ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study |
title_fullStr | ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study |
title_full_unstemmed | ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study |
title_short | ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study |
title_sort | esr1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219866/ https://www.ncbi.nlm.nih.gov/pubmed/21541733 http://dx.doi.org/10.1007/s13402-011-0045-5 |
work_keys_str_mv | AT moelanscathyb esr1amplificationisrareinbreastcancerandisassociatedwithhighgradeandhighproliferationamultiplexligationdependentprobeamplificationstudy AT monsuurhanneken esr1amplificationisrareinbreastcancerandisassociatedwithhighgradeandhighproliferationamultiplexligationdependentprobeamplificationstudy AT depinthjohannesh esr1amplificationisrareinbreastcancerandisassociatedwithhighgradeandhighproliferationamultiplexligationdependentprobeamplificationstudy AT radersmaremcod esr1amplificationisrareinbreastcancerandisassociatedwithhighgradeandhighproliferationamultiplexligationdependentprobeamplificationstudy AT dewegerroela esr1amplificationisrareinbreastcancerandisassociatedwithhighgradeandhighproliferationamultiplexligationdependentprobeamplificationstudy AT vandiestpaulj esr1amplificationisrareinbreastcancerandisassociatedwithhighgradeandhighproliferationamultiplexligationdependentprobeamplificationstudy |